Waltham's Morphic Therapeutic inks $100M deal with AbbVie
A preclinical Waltham biotech company is hoping to launch its first clinical trial of a fibrosis treatment next year after signing a $100 million collaboration agreement with AbbVie this week.
Morphic Therapeutic is partnering with AbbVie to develop drugs that could halt organ-harming tissue buildup resulting from chronic inflammation in the lungs or liver. AbbVie (NYSE: ABBV) will pay $100 million up front for exclusive licensing rights to any drugs developed, and will be responsible f or global…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Allison DeAngelis Source Type: news
More News: American Health | Biotechnology | Clinical Trials | Health Management | Liver | Urology & Nephrology